Functional Study of the Human BRCA2 Tumor Suppressor
Abstract
My research is focused on the BRCA2 protein, whose mutations have been implicated in the development of breast, ovarian, male breast, prostate, pancreatic cancers and Fanconi anemia. It is intended to elucidate some of the biological functions of BRCA2 and/or regulation of its in vivo function through generation/utilization of new reagents and identification of new BRCA2 interacting proteins. During this second year of grant support, I was able to identify a completely novel protein, named CLB2 in this study, as a major physiological partner of BRCA2. I discovered that CLB2 is a chromatin bound protein and is required for BRCA2's chromatin binding. In light of these findings, it is attempting to speculate that disruption of CLB2 function would lead to significant impairment of BRCA2's tumor suppressor function realized at least in a large part through its DNA recombination/repair activity which presumably requires its docking to the chromatin.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2004
- Accession Number
- ADA432411
Entities
People
- Bing Xia
- David M. Livingston
Organizations
- Dana–Farber Cancer Institute